Kit for monitoring biomarker of IgA nephropathy

Abstract

The invention provides a kit for monitoring or detecting a pathogenetic process and / or a therapeutic process of IgA nephropathy. The kit comprises a PCR primer for detecting a small RNA biomarker, wherein the biomarker is selected from miR-15a, miR-16, miR-21, miR-29a, miR-34a, miR-125b, miR-141, miR-148b, miR-155, miR-184, miR-192, miR-200a, miR-200b, miR-200c, miR-204, miR-205, miR-210, miR-301aand miR-429. The kit can be used for excellently detecting the therapeutic process.

Description

technical field [0001] The invention belongs to the field of medical detection and relates to a kit for discovering biomarkers for monitoring IgA nephropathy. Background technique [0002] IgA nephropathy (IgA nephropathy, IgAN) is the most common primary glomerulonephritis in the world. Although the prevalence of IgAN in the general population is low, its prevalence is high, especially in Asia, estimated at 30–40% in renal biopsies. Approximately 30-40% of IgAN patients will progress to end- (ERSD) within 20-30 years, making IgAN the leading cause of ERSD worldwide. However, the pathogenesis of IgAN remains unclear and available treatments only relieve symptoms and delay the need for dialysis and kidney transplantation. Among patients with IgAN, some respond well to treatment and maintain renal function for long periods of time, however, it is less understood that some patients are resistant to treatment and require dialysis more rapidly, and that mortality in IgAN patien...

AI Technical Summary

Problems solved by technology

Kidney biopsy is invasive and can lead to complications and is not suitable for monitoring disease progression

Images